Navigation Links
Lotus Pharmaceuticals, Inc.'s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
Date:9/25/2008

BEIJING, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a pharmaceutical products developer, manufacturer and distributor in the People's Republic of China ("PRC"), today announced that China's State Food and Drug Administration (SFDA) is evaluating the Company's drug Laevo-Bambutero for clinical trials.

Laevo-Bambutero is a drug used to treat asthma, and the Company views it as a more effective drug than a number of alternative drugs currently on the market. Lotus obtained the patent along with exclusive production rights in China for Laevo-Bambutero through a technology transfer agreement with Dongguan Kaifa Biomedicine, Inc. in May 2008.

The Company received formal notice from the SFDA that it has started to evaluate Laevo-Bambutero for clinical trials. This evaluation is expected to take from six to nine months and will determine if and when stringent clinical trials begin. If approved, those clinical trials should take approximately eighteen months. Pending final approval for manufacturing and distribution from the SFDA, Lotus plans to launch sales of Laevo-Bambutero by 2012.

"The news from the SFDA is an important first step of many steps needed for bringing Laevo-Bambutero to market," said Dr. Zhongyi Liu, Chairman, CEO and President of Lotus Pharmaceuticals, Inc. "We are pleased to have reached a new milestone in the commercialization of Laevo-Bambutero, which we look forward to adding to our product portfolio."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. controls and operates Liangfang Pharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd. ("Enze"), two pharmaceutical companies located in Beijing, China. Together, Liangfang and Enze ("Lotus East") undertake the development, production, marketing and distribution of pharmaceutical products. Lotus East has some of the most advanced pharmaceutical production equipment in China and its manufacturing facilities meet national Good Manufacturing Practices (GMP). The Company distributes its own portfolio of drugs and pharmaceutical products produced by other manufacturers in the PRC through an extensive national distribution network. Lotus owns ten pharmacies in Beijing through which it directly sells over 5,000 western drugs, Traditional Chinese Medicines (TCM) and medical equipment items.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K filed with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact:

Lotus Pharmaceuticals, Inc.

Mr. Adam Wasserman, CFO

Phone: +1-877-801-0344

Email: info@LotusEast.com

Web site: http://www.lotuseast.com

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web site: http://www.ccgir.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
3. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
6. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
7. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
9. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
10. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
11. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
(Date:7/5/2017)... Pace Analytical, a company of over 2,000 employees and a leader in environmental ... Sciences, further solidifying their position as the top American owned and operated environmental ... ... Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative full ...
(Date:6/30/2017)... -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug ... forms of existing biologically active molecule. ... Subveta oral spray ... formula, which is designed to prevent precipitation of the active ... provide fast onset of action and is designed to optimize ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... The Ellis Agency, ... with the Epilepsy Foundation in a community wide charity event with the goal of ... Sunde, a young local woman who lives with epilepsy, recently launched a charity campaign ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated ... life a decade after surgery, though activity levels decline over time. The study, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
Breaking Medicine News(10 mins):